Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Entera Bio Ltd. - Ordinary Shares
(NQ:
ENTX
)
2.920
+0.050 (+1.74%)
Streaming Delayed Price
Updated: 3:40 PM EDT, Aug 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Entera Bio Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
Entera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise
↗
August 07, 2026
Via
Chartmill
Entera Announces Second Quarter 2026 Financial Results and Business Updates
August 07, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
August 04, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 31, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Which stocks are moving on Monday?
↗
July 27, 2026
Via
Chartmill
Curious about the most active stocks on Monday?
↗
July 27, 2026
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
July 27, 2026
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved...
Via
Benzinga
Monday's session: top gainers and losers
↗
July 27, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
July 27, 2026
Via
Chartmill
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
July 27, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
What's going on in today's after hours session
↗
June 22, 2026
Via
Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session.
↗
June 22, 2026
Via
Chartmill
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
June 22, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
June 16, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
June 15, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Get insights into the top gainers and losers of Friday's after-hours session.
↗
May 08, 2026
Via
Chartmill
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
May 08, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
April 14, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
April 02, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead
↗
February 11, 2026
Entera Bio said that the company chairman Geno J. Germano bought shares, in addition to directors Steven D. Rubin, Haya Taitel, and Sean Ellis.
Via
Stocktwits
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
October 20, 2025
Via
AB Newswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 15, 2025
Via
Benzinga
Could Oral Osteoporosis Treatment Become the Next GLP-1-Style Blockbuster?
October 08, 2025
Via
AB Newswire
Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
August 22, 2025
Via
AB Newswire
Entera Bio Beats Q2 EPS Estimates
↗
August 08, 2025
Via
The Motley Fool
Topics
Intellectual Property
ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024
↗
August 12, 2024
ENTX stock results show that Entera Bio met analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
↗
July 23, 2024
These are the meme stocks to buy as they represent fundamentally strong ideas with major growth acceleration catalysts.
Via
InvestorPlace
3 Meme Stocks That Can Surge by 200% Before 2025
↗
July 08, 2024
Don't wait too long on these attractive meme stocks to buy for 200% upside, as they represent good businesses with growth catalysts.
Via
InvestorPlace
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
↗
July 02, 2024
These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline.
Via
InvestorPlace
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
